Cancer Therapy and Treatments During COVID-19 Era

Overview

Journal Adv Biol Regul

Publisher Elsevier

Specialties Biochemistry
Molecular Biology

Date 2020 Aug 11

PMID 32773105

Citations 18

Authors

Shaw M Akula

Stephen L Abrams

Linda S Steelman

Saverio Candido

Massimo Libra

Kvin Lerpiriyapong

Lucio Cocco

Giulia Ramazzotti

Stefano Ratti

Matilde Y Follo

Alberto M Martelli

William L Blalock

Manuela Piazzi

Giuseppe Montalto

Melchiorre Cervello

Monica Notarbartolo

Jorg Basecke

James A McCubrey

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disease progression. This review article will summarize how the treatments of various cancer patients has changed during the COVID-19 era as well as discuss the promise of some existing drugs and other agents to be repurposed to treat this disease.

Citing Articles

Joseph A, Shour A, Lasebikan N, Jimoh M, Adegboyega B, Nwachukwu E Clin Med Res. 2024; 22(2):61-75.

PMID: 39231622 PMC: 11374496. DOI: 10.3121/cmr.2024.1854.

The effect of the earliest COVID-19 outbreak on survival in uninfected advanced NSCLC patients receiving chemotherapy in Jiangsu Province, China: A retrospective cohort study.

Lu H, Wang Y, Feng G, Shen C, Zhou X, Han J Medicine (Baltimore). 2023; 102(39):e34559.

PMID: 37773874 PMC: 10545141. DOI: 10.1097/MD.0000000000034559.

The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients.

Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R J Gastrointest Cancer. 2022; 54(2):492-500.

PMID: 35445343 PMC: 9020757. DOI: 10.1007/s12029-022-00820-4.

Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).

Li Y, Ren H, Cao J Int J Oncol. 2022; 60(4).

PMID: 35234272 PMC: 8923649. DOI: 10.3892/ijo.2022.5332.

Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation.

Spencer K, Singer E, Girda E J Cancer Biol. 2022; 2(3):75-82.

PMID: 35224563 PMC: 8870506. DOI: 10.46439/cancerbiology.2.029.

References

Singh A, Berman A, Marmarelis M, Haas A, Feigenberg S, Braun J . Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncol Pract. 2020; 16(9):579-586. DOI: 10.1200/OP.20.00286. View

Rogado J, Obispo B, Pangua C, Serrano-Montero G, Martin Marino A, Perez-Perez M . Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol. 2020; 22(12):2364-2368. PMC: 7246222. DOI: 10.1007/s12094-020-02381-z. View

Vrachimis A, Iakovou I, Giannoula E, Giovanella L . ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer. Eur J Endocrinol. 2020; 183(1):G41-G48. PMC: 7938009. DOI: 10.1530/EJE-20-0269. View

Bernhardt D, Wick W, Weiss S, Sahgal A, Lo S, Suh J . Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas. Neuro Oncol. 2020; . PMC: 7239150. DOI: 10.1093/neuonc/noaa113. View

Viale G, Licata L, Sica L, Zambelli S, Zucchinelli P, Rognone A . Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. Oncologist. 2020; 25(7):e1013-e1020. PMC: 7272798. DOI: 10.1634/theoncologist.2020-0316. View

Gurwitz D . Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining. Drug Dev Res. 2020; 81(7):777-781. PMC: 7276810. DOI: 10.1002/ddr.21689. View

McCubrey J, Lertpiriyapong K, Steelman L, Abrams S, Yang L, Murata R . Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY). 2017; 9(6):1477-1536. PMC: 5509453. DOI: 10.18632/aging.101250. View

Mazzone P, Gould M, Arenberg D, Chen A, Choi H, Detterbeck F . Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Chest. 2020; 158(1):406-415. PMC: 7177089. DOI: 10.1016/j.chest.2020.04.020. View

Chen H, Wu X, Wang W, Wang Q . When cancer encounters COVID-19 in China: what have we suffered, experienced and learned. Jpn J Clin Oncol. 2020; 50(6):712-717. PMC: 7239118. DOI: 10.1093/jjco/hyaa077. View

10.

Freedman R, Sedrak M, R Bellon J, Block C, Lin N, King T . Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. 2020; 113(4):355-359. PMC: 7313961. DOI: 10.1093/jnci/djaa079. View

11.

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

12.

Lionakis M, Dunleavy K, Roschewski M, Widemann B, Butman J, Schmitz R . Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. 2017; 31(6):833-843.e5. PMC: 5571650. DOI: 10.1016/j.ccell.2017.04.012. View

13.

Lucarini L, Durante M, Lanzi C, Pini A, Boccalini G, Calosi L . HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway. J Cell Mol Med. 2016; 21(2):324-335. PMC: 5264150. DOI: 10.1111/jcmm.12967. View

14.

Jafari A, Dadkhahfar S, Perseh S . Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. Crit Rev Oncol Hematol. 2020; 151:102982. PMC: 7217119. DOI: 10.1016/j.critrevonc.2020.102982. View

15.

Kim J, Suk M, Yoon D, Kim H, Jung K, Kang E . Inflammatory and transcriptional roles of poly (ADP-ribose) polymerase in ventilator-induced lung injury. Crit Care. 2008; 12(4):R108. PMC: 2575597. DOI: 10.1186/cc6995. View

16.

McCubrey J, Abrams S, Lertpiriyapong K, Cocco L, Ratti S, Martelli A . Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. Adv Biol Regul. 2017; 67:190-211. DOI: 10.1016/j.jbior.2017.09.012. View

17.

Baumann B, MacArthur K, Brewer J, Mendenhall W, Barker C, Etzkorn J . Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer. 2020; 126(17):3900-3906. PMC: 7301000. DOI: 10.1002/cncr.32969. View

18.

Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L . Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020; 146(1):137-146.e3. PMC: 7250105. DOI: 10.1016/j.jaci.2020.05.019. View

19.

Tutuncuoglu B, Cakir M, Batra J, Bouhaddou M, Eckhardt M, Gordon D . The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2. Cancer Discov. 2020; 10(7):916-921. PMC: 7357668. DOI: 10.1158/2159-8290.CD-20-0559. View

20.

Kuderer N, Choueiri T, Shah D, Shyr Y, Rubinstein S, Rivera D . Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241):1907-1918. PMC: 7255743. DOI: 10.1016/S0140-6736(20)31187-9. View